| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06072781 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous… | Low Grade Serous Ovarian Cancer | Recruiting |
| Phase 2 | |||
| NCT06007924 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Thyroid Cancer | Recruiting |
| NCT06495125 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory… | Advanced Lung Adenocarcinoma | Recruiting |
| NCT07126158 | Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic… | Pancreatic Adenocarcinoma | Recruiting |
| NCT06394804 | A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous… | Low-Grade Serous Ovarian Cancer | Recruiting |
| NCT05787561 | A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic… | Mesonephric Gynecologic Cancer | Recruiting |
| NCT06369259 | Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib… | Advanced Colorectal Cancer | Recruiting |
| NCT04331041 | Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas… | Pancreas Cancer | Active, Not Recruiting |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced… | Advanced Lymphoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06630260 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours | Glioblastoma Multiforme (GBM) | Recruiting |
| Phase 1 | |||
| NCT05636514 | Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS | Myelodysplastic Syndromes | Recruiting |
| NCT07318324 | Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant… | Phase IB | Not Yet Recruiting |
| NCT03875820 | Phase I Trial of Defactinib and VS-6766. | NSCLC | Active, Not Recruiting |